CH Biotech R&D Co., Ltd. (6534) AI Stock Analysis

CH Biotech R&D Co., Ltd.

(TWSE:6534)

Select Model

Rating:75Outperform

Price Target:TWD 96.00▲(12.68% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is supported primarily by strong financial performance and attractive valuation. Weak technical momentum and declining profitability trends reduce the overall rating.

Positive Factors

High ProfitabilitySustained very high gross margins and strong operating profitability indicate meaningful earnings power in the business model. These margins provide capacity to fund research, commercialization, and shareholder returns while offering a durable buffer against moderate cost pressure.

Negative Factors

Slowing Revenue GrowthThe sharp cooling in revenue growth suggests that the company’s expansion rate has moderated after earlier acceleration. Slower top-line growth can reduce operating leverage, limit the pace of reinvestment, and place greater importance on successfully developing new products or applications.

CH Biotech R&D Co., Ltd. (6534) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 8.64B
Dividend Yield: 6.23%
Average Volume (3M): 58.16K
Price to Earnings (P/E): 15.0
Beta (1Y): 0.07
Revenue Growth: 6.31%
EPS Growth: 31.07%
Country: TW
Employees: 200
Sector: General
Sector Strength: 55
Industry: Agricultural Inputs

CH Biotech R&D Co., Ltd. Business Overview & Revenue Model

Company Description

CH Biotech R&D Co., Ltd. is a company dedicated to the creation and worldwide supply of agricultural chemicals rooted in biotechnology. Their commercial footprint spans Taiwan, the United States, Canada, Australia, Brazil, Argentina, Uruguay, and Chi...

CH Biotech R&D Co., Ltd. Financial Statement Overview

Summary

Strong profitability, balance-sheet quality, and improving leverage support the score. Declining margins, lower return on equity, and moderate cash-conversion risk are limiting factors.

Income Statement

84Very Positive

Balance Sheet

89Very Positive

Cash Flow

78Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.87B	1.82B	1.64B	1.51B	1.43B	1.02B
Gross Profit	1.53B	1.36B	1.36B	1.26B	1.13B	847.95M
EBITDA	879.00M	837.25M	797.71M	761.56M	722.29M	470.20M
Net Income	604.68M	463.79M	476.39M	463.29M	465.42M	291.50M
Balance Sheet
Total Assets	3.81B	3.57B	3.63B	3.65B	3.20B	3.03B
Cash, Cash Equivalents and Short-Term Investments	640.73M	397.27M	482.13M	943.00M	533.10M	326.79M
Total Debt	868.36M	664.33M	747.33M	845.16M	894.89M	1.12B
Total Liabilities	1.17B	888.48M	982.44M	1.13B	1.11B	1.31B
Stockholders Equity	2.63B	2.69B	2.65B	2.52B	2.09B	1.72B
Cash Flow
Free Cash Flow	741.37M	465.68M	-51.51M	542.89M	581.35M	192.43M
Operating Cash Flow	897.01M	589.02M	538.44M	659.15M	698.97M	264.36M
Investing Cash Flow	-159.93M	-141.52M	-594.77M	-142.89M	-117.22M	-44.75M
Financing Cash Flow	-727.25M	-530.39M	-406.21M	-106.60M	-375.37M	-222.06M

CH Biotech R&D Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6534 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:6534	75Outperform	TWD 8.35B	15.04	―	6.23%	6.31%	31.07%
TW:4162	70Outperform	TWD 7.43B	14.16	―	3.81%	-58.69%	-66.96%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4169	54Neutral	TWD 7.93B	-291.25	―	0.27%	―	―
TW:4128	44Neutral	TWD 7.85B	24.61	―	―	4.85%	―
TW:6541	43Neutral	TWD 7.47B	-5.03	-26.61%	―	207.37%	4.17%

* General Sector Average

Performance Comparison

TW:6534 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6534	CH Biotech R&D Co., Ltd.	85.20	-3.49	-3.93%
TW:6541	Tanvex Biopharma	28.15	-27.35	-49.28%
TW:4128	Microbio Co., Ltd.	13.45	-6.85	-33.74%
TW:4162	PharmaEngine, Inc.	52.50	-17.18	-24.66%
TW:4169	TCM Biotech International Corp.	116.50	-63.27	-35.20%
TW:7832	Intelligene Inc	13.15	1.00	8.23%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

CH Biotech R&D Co., Ltd. AI Stock Analysis